The generation of hemagglutinin monoclonal antibodies against H9N2 influenza virus

H9N2 avian influenza viruses (AIVs) are widely distributed, causing continuous outbreaks in poultry and sporadic infections in humans.

Vaccination is the primary method used to prevent and control H9N2 AIV infection.

However, the ongoing evolution and mutation of AIVs often result in limited protection effects from vaccines.

Therapeutic monoclonal antibodies (mAbs) targeting influenza viruses offer a promising alternative.

In this study, we immunized mice with inactivated H9N2-W1 virus, and we screened and acquired five mAbs, namely 4D12, F4, 5C8, 2G8 and A11.

We showed that all five mAbs specifically targeted the HA protein of various H9N2 AIV strains.

In vitro neutralization tests demonstrated that all five mAbs exhibited neutralization activity against H9N2 AIVs, with mAb F4 displaying the most potent neutralization effect.

The F4 mAb exhibited dose-dependent preventive and therapeutic effects against lethal H9N2-115 infection, and the administration of F4 at a dose of 3 μg/g provided complete protection in vivo.

Our study presents an alternative approach for preventing and controlling H9N2 AIV infection.

Furthermore, the identified F4 mAb holds promise as a solution to potential pandemics in humans caused by H9N2 AIVs.